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Orthotopic hepatic transplantation offers 
selected patients a surgical cure of their otherwise 
hopelessly advanced liver disease. It also presents 
the medical-scientific community with an almost 
limitless list of new questions to be asked, unique 
materials to be studied, and an opportunity to 
extend the current understanding of liver disease 
and its complications. Presented below is a list of 
five major areas of research that orthotopic liver 
transplantation has made possible, the list certainly 
is not all-inclusive. These topics have been selected 
as examples of the investigative areas in liver disease 
that should benefit dramatically as a consequence 
of the increasing performance of the procedure and 
the involvement of more and new investigative 
groups in transplant programs. They are: (1) preser-
vation of the liver; (2) hepatic regeneration; (3) the 
pathogenesis of various unusual metabolic liver dis-
eases; (4) the immune mechanisms involved in rejec-
tion as well as in various primary hepatic diseases; 
and (5) the problem of hepatic encephalopathy, its 
pathogenesis, consequences, and reversibility. Each 
of these major areas of investigative interest to 
hepatologists and hepatic surgeons will be discussed 
individually. 
HEPATIC PRESERVATION 
The present technique of hepatic removal from 
the donor and method of cold storage of the organ 
in an iced solution of fluid resembling intracellular 
fluid is well known and widely used. The method 
has certain advantages: its relative simplicity and its I 
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comparability to that used for other organs also 
being harvested for transplaptation from the same 
donor. However, this technique severely limits the 
number of donor organs available to a potential 
recipient because of the limited ex vivo life-span of 
the donor organ. This is probably no greater than 
12 to 14 hours maximally, and ideally should be no 
longer than 6 to 8 hours for optimum early graft 
survival. Ideally, for maximal donor use and better 
organ recipient matching, possibly with tissue 
typing, donor organs should be able to survive for 
periods of 24 to 36 hours with good postimplanta-
tion function. Such a time frame would allow donor 
organs from anywhere in the world to be harvested 
and used either where the need for an organ is most 
critical or where the donor organ is best suited for a 
given recipient. 
HEPATIC REGENERATION 
Despite the current best technique of organ 
harvesting and rapid engraftment, some degree of 
ischemic injury occurs in each organ grafted. Such 
injury requires hepatic graft regeneration for its 
resolution and subsequent maximal function in the 
recipient. 
In some cases, the donor organ is larger than 
anticipated and thus may have to be reduced in size 
surgically for successful engraftment. As a conse-
quence of such reductional surgery, the donor 
organ experiences an additional injury that necessi-
tates an additional regenerative response, following 
successful engraftment in the recipient, for maximal 
postimplantation function. Less often, but also 
fairly common, is the circumstance of a donor 
organ that is too small for a given recipient. Under 
such circumstances, an intact, small organ is not of 
sufficient size to return the recipient to a state of 
maximal or ideal hepatic function. In such cases, 
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the donor organ can be seen to increase rapidly in 
size, presumably as a consequence of hepatic re-
generation, until the donor organ more closely 
matches the required hepatic mass of the recipient 
for putative ideal function.9,lD 
In addition, it should be remembered that the 
rejection process is continual. Thus, maximal 
hepatic function in a successfully engrafted organ 
requires the continual replacement of hepatocytes 
and cholangiolar cells destroyed by the immune 
system as well as those lost by simple attrition over 
time. 
The liver graft responds to each of these puta-
tive injuries, at least in part, by the process of 
hepatic regeneration. Thus, a better understanding 
of the process of regeneration is crucial to any fur-
ther improvements in the results of clinical hepatic 
transplantation. Importantly, it must be recognized 
that the signals and factors that regulate the regen-
erative responses of the engrafted liver to each of 
these putative injuries may be quite different. 
Specifically, hepatic transplantation has shown that 
the issue of hepatic regeneration is considerably 
more complex than the current simple models, all of 
which involve the idea of recruitment of new hepa-
tocytes,9,10 and suggests that the only important 
clinical problem requiring hepatic regeneration is 
that of massive hepatic necrosis. Thus, new models 
of hepatic regeneration will have to be formulated 
and developed to answer specific questions related 
to issues of liver transplantation. Such models will 
have to address the more specific signals for and 
controls of the regenerative process. They may also 
provide important additional information so that 
the entire process of hepatic regeneration can be 
better understood and possibly even manipulated 
specifically, as may be required by a given clinical 
situation.!! 
RECOGNITION, PATHOGENESIS, AND 
CORRECTION OF METABOLIC AND 
OTHER UNUSUAL LIVER DISEASE 
The development of a liver transplant center 
that offers a therapeutic option to patients with 
otherwise untreatable liver disease serves as a focus 
for the referral of such cases. As a consequence of 
such referrals, clinicians in transplant centers see 
many more cases of "obscure" liver disease than do 
clinicians at major medical referral centers, includ-
ing centers of hepatic expertise not having a trans-
plant program.!1 As a direct result of such intensi-
fied clinical experience with liver disease, clinical 
signs of and unusual presentations of the less com-
mon metabolic liver diseases become recognized. 
Moreover, better methods of caring for such 
patients until transplantation is required can be de-
veloped and validated by clinical trials. In addition, 
epidemiologic studies become possible to evaluate 
clues to pathogenesis as well as to examine factors 
that modulate the clinical expression and/or rate of 
progression of such diseases. An easy example is 
that of alphal-antitrypsin disease. Why do some 
individuals with this disease develop liver disease 
and others develop pulmonary disease? Why do 
some individuals with alpha I-antitrypsin deficiency 
develop clincially evident liver disease as children 
and others only as adults? Another example is the 
problem of biliary atresia and the various biliary 
hypoplasia syndromes. Are these many diseases or 
simply variable expressions of a single disease? Are 
they environmentally determined? Certainly, many 
other interesting questions can be generated and will 
be addressed in the future. 
Already, new insights into the specific defects 
of Wilson's disease, alpha I-antitrypsin deficiency, 
tyrosinemia, and other such diseases are being made 
or are being pursued by investigators located at 
transplant centers.!2 With the availability of the 
entire resected diseased liver, the problem of insuf-
ficient amount of tissue sample, such as is frequent-
ly required for sophisticated biochemical and 
genetic engineering studies, should no longer exist. 
Furthermore, the identification of individual 
metabolic liver diseases in biochemical terms as well 
as the genetic site of the defect in terms of its 
chromosomal location, nucleic acid base pair altera-
tions, and gene product abnormality should be re-
solvable. The answers to such questions may pro-
vide alternative therapies to transplantation, such as 
correct (normal) gene product replacement or the 
development of alternative medical therapies based 
on a better understanding of the specific disease 
process involved. 
IMMUNOLOGIC DISEASES AND THE 
IMMUNE RESPONSE 
Certainly as a direct consequence of hepatic 
transplantation, new data concerning the immuno-
logic characteristics of the liver will be obtained. 
Specifically, the cellular sites of the liver that elicit 
an immune response will be identified and charac-
terized. New technologies will be developed to limit 
or modify the immunologic reactivity of these 
hepatic tissues and the body's way of reacting to 
them. Already, the histopathology of early and late 
rejection has been characterized using the light 
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microscope and standard staining methods.8,13-IS 
Data concerning the specific phenotypic characteris-
tics of the lymphoid cells found in areas of and ad-
jacent to the rejection process are also forthcoming. 
Eventually, these cells will be isolated, cloned, and 
characterized functionally as well as phenotypically. 
Recently, it has been shown that bile ductular 
cells express HLA antigens, and it has been sug-
gested that this is the reason that the bile ductules 
appear to be selectively destroyed as a consequence 
of the immune response associated with rejection. 13 
This finding of bile ductular expression of HLA 
antigens has been demonstrated also in primary 
biliary cirrhosis and graft versus host disease, two 
disease processes that are characterized also by the 
presence of bile ductular destruction. This fact 
probably provides the reason for the histopatho-
logic similarity between primary biliary cirrhosis, re-
jection, and graft versus host disease. Whether 
individuals with primary sclerosing cholangitis will 
also express HLA antigens in the areas of their 
liver, which are being destroyed by a mixed inflam-
matory infiltrate, needs yet to be determined. Data 
concerning the nature of the cellular infiltrates 
present in late liver disease due to primary 
sclerosing cholangitis are already available. Whether 
similar findings will be evident in early disease re-
mains to be determined. 
Certainly, a question that will need to be 
answered is, if chronic active hepatitis is the 
consequence of an immune response directed at the 
liver, why does it differ so markedly from the histo-
logic appearance of rejection? It appears certain 
from the available data that the recognition sites for 
the immune response in each must be different, 
being the hepatocyte in the case of chronic active 
hepatitis and predominantly bile ductular cells in re-
jection. Similarly, what are the immunologic signals 
that exist between immunologically responsive cells 
that help to explain the differences between the two 
conditions? Moreover, if cyclosporine and pred-
nisone can either prevent or markedly reduce the 
process of rejection, why are they so inconsistent 
or poor in their ability to modulate the immune 
response that results in chronic active hepatitis? 
These questions are but a few of the many that will 
be asked and answered in the next several years as 
we follow patients with transplants and care for 
those awaiting transplantation. 
Hepatic Encephalopathy 
Hepatic encephalopathy has been a problem of 
keen interest to physicians, particularly hepatolo-
gists, since the very dawn of medicine. We have 
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been taught that the central nervous system cannot 
repair itself once injured. We have been taught also 
that there are histologic findings that are charac-
teristic of chronic portal-systemic encephalopathy 
(PSE). Certainly, the condition of patients demon-
stration PSE tends to wax and wane, as does the 
course of their liver disease, and particularly the 
extrahepatic parameters that modulate the residual 
hepatic function present in patients with PSE. Can 
the central nervous system in such patients, follow-
ing transplantation and the return of normal 
hepatic function, repair itself and return to normal 
or can it only return to some baseline of "disease" 
that allows the patient to be quite functional but 
nonetheless quantitatively abnormal? Preliminary 
data obtained 1 year after liver transplantation sug-
gest that the brain does, in fact, improve, but that it 
has not entirely returned to normal, at least at the 
I-year follow-up point.16 Will it ever? If so how 
long will it take? If not, what residual defects will 
remain? What will be their significance? How 
should we follow and monitor such patients? Are 
there special precautions we should suggest to pa-
tients who are successfully transplanted, but yet 
continue to express evidence of PSE? 
Interestingly, preliminary data suggest that the 
specific pathophysiologic nature of the liver disease 
affects the type of neuropsychologic defects identifi-
able in patients with PSE.17 ,18 This suggests that 
the reason for the transplant (the primary liver 
disease) may determine the rate and degee of neuro-
psychologic improvement expected to occur in a 
given patient after successful transplantation. More-
over, it suggests that the specific underlying patho-
physiologic basis for PSE may differ in each 
etiologic case. Thus, specific, rather than (or at 
least, in addition to) generic, modalities, such as 
lactulose, a low protein diet, and neomycin, may be 
indicated for patients awaiting transplantation and 
manifesting evidence of PSE. These and many other 
important questions concerning PSE will be answer-
ed in the next decade, at least in part as a conse-
quence of the ability to transplant patients success-
fully, thereby correcting their liver disease and 
simply following them and collecting data in a 
prospective manner. 
Who Pays for Liver Transplantation 
and the Knowledge that Accrues from It? 
The answer to this question is multifactorial 
and varies as to what specifically is intended by 
either the question or the answer. 19 For example, 
the patient pays, his insurance carrier pays, the 
National Institute of Health (NIH) pays, and the 
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physician (surgeon/hepatologist) pays. Moreover, 
individual benefactors, foundations, pharmaceutical 
companies, and many others have paid and continue 
to pay for such knowledge. 
The patient pays by experiencing first hand the 
complications, problems, and difficulties associated 
with his or her liver disease. Moreover, only the pa-
tient undergoes the rigors of the preoperative 
evaluation, the fear of having or not having the 
operation, the operation itself, the postoperative 
recovery period, the fear of the actual experience of 
a rejection episode, and a life after successful trans-
plantation complicated by the need to take and pay 
for costly immunosuppressive agents, worry about 
opportunistic infections and the unknown possibility 
of recurrent or even new liver disease. Thus, the pa-
tient continues to be an experimental model, 
thereby repaying the debt owed former transplant 
patients and pointing the way toward a better 
method of transplantation and rejection prevention 
and control for transplant recipients of the future. 
The insurance company pays by assuming the 
cost of the transplant procedure and its evaluation 
for one of its insured. It has accepted such respon-
sibility by accepting premiums from the insured and 
has done so expecting to make a profit by amor-
tizing the costs of the procedure over the cost of the 
insurance provided a much larger subscriber popu-
lation, most of whom are not expected to require 
the procedure. It should be noted, however, that in-
surance carriers only pay for required services and 
procedures. They do not and have not paid directly 
for any research that has been or continues to be 
accomplished using their subscribers. 
The various insurance companies and programs 
that have paid for a liver transplant in Pittsburgh 
are shown in Table 1. This is not an all-inclusive 
listing of companies that may have paid for or are 
willing to pay for liver transplantation. It is only a 
listing of those who have paid for one of their sub-
scribers to have a transplant or a specific institution 
to date. 
The NIH have paid and continue to pay by 
supporting grants and contracts directed toward 
issues related to liver transplantation. Tables 2 and 
3 document the agencies within the NIH that have 
TABLE 1. Insurance Providers that Have Paid for a Liver Transplant in Pittsburgh 
Commercial Insurance Companies 
Aetna Life 
Allstate 
American Postal Workers 
Bankers Life 
Continental Life 
Connecticut General 
Educators Mutual 
Equitable Life 
Fireman's Fund 
Firestone Tire & Rubber 
John Hancock Life 
Liberty Mutual 
Lincoln National 
Metropolitan Life 
Mutual Benefit Life 
Motorola 
Blue Cross Plans 
Capitol (Harrisburg, P A) 
Central Ohio (Columbus) 
Connecticut 
Delaware 
Georgia 
Greater New York 
Greater Philadelphia 
Idaho 
Illinois 
Indiana 
Lehigh Valley (Allentown) 
Louisiana 
Massachusetts 
Michigan 
Mississippi 
Montana 
National Association of Letter Carriers New Hampshire 
New England Life New Jersey 
New York Life North Dakota 
Pilot Life 
Prudential Life 
Time Insurance 
Travelers Life 
Sheet Metal Welfare Fund 
Northeastern Ohio 
(Cleveland) 
Northern California 
(Oakland) 
Oklahoma 
Rhode Island 
Rochester, New York 
South Carolina 
Tennessee 
Texas 
Vermont 
Western Pennsylvania 
(Pittsburgh) 
State Governments 
(Medicaid) 
Kentucky 
Massachusetts 
Missouri 
New Jersey 
New Mexico 
New York 
Pennsylvania 
Ohio 
South Dakota 
Federal Government 
Armed Services 
Champus 
Veterans Administration 
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TABLE 2. Funds Expended by NIH by Institute* for 
Liver Transplantation Research and Development 
Year NIADDK NCT DRR NHLBI NIAID Total 
1972 406,883 42,942 74,707 63,004 237,495 825,031 
1973 263,794 184,151 33,021 151,324 236,353 868,643 
1974 246,975 192,859 31,809 168,501 0 640,144 
1975 152,629 208,959 100,007 87,671 82,961 632,227 
1976 242,249 166,926 115,342 17,440 89,054 631,011 
1977 288,629 26,805 145,861 0 312,980 774,275 
1978 280,069 182,144 129,794 0 109,782 701,789 
1979 197,631 156,672 138,303 0 120,111 612,717 
1980 265,060 43,583 132,189 0 0 440,832 
1981 252,055 189,562 111,364 0 0 552,981 
1982 318,313 143,743 73,204 0 0 535,260 
1983 525,761 215,098 27,330 0 140,916 909,135 
1984 954,417 181,884 45,378 0 161,762 180,959 
1985 1,211,923 231,571 50,941 0 180,959 1,675,394 
Total 11,142,888 
*NIADDK: National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases; NCI: Nation-
at Cancer Institute; DRR: Division Research Resources; NHLBI: National Heart, Lung, and 
Blood Institute; NIAID: National Institute of Allergy and Infectious Diseases. 
supported liver transplant-directed research (Table 
2) and the types of awards funded (Table 3) on an 
annual basis from 1972 through most of 1985. This 
listing of governmental support is not complete, in 
that only, the NIH data were available for review. 
The Alcohol, Drug Abuse, and Mental Health Ad-
ministration (ADAMHA) and other agencies may 
have funded, at least in part, research related to 
transplantation, but no data about such support 
were available for our review. Moreover, the listings 
in Tables 2 and 3 are minimum figures chosen from 
a listing of the titles of the awards for each of the 
years cited. Had a research project title not included 
TABLE 3. Types of Grant Awards Expended by NIH 
for Liver Transplantation Research and Development 
Regular Program 
Year Grant Project CRC* Contract Total 
1972 5 9 7 0 21 
1973 4 14 6 0 24 
1974 3 9 4 0 16 
1975 3 9 4 0 16 
1976 3 11 4 0 18 
1977 5 9 7 0 21 
1978 5 9 3 0 17 
1979 5 6 2 0 13 
1980 4 3 3 0 10 
1981 4 2 4 0 10 
1982 3 2 0 0 5 
1983 6 0 3 0 9 
1984 8 4 0 13 
1985 9 4 0 14 
Total 207 
*CRC: Clinical Research Centers. 
a reference to transplantation of the liver, it would 
not have been considered for inclusion in either of 
the tables. 
In addition, the physicians and scientists in-
volved in the broad area of liver transplantation 
have paid by spending hours in the care of patients, 
collecting and reporting data on patients and 
animals, and by taking the risks associated with the 
use of a novel form of treatment before it has 
become accepted generally by the medical establish-
ment. Much of this effort has been without finan-
cial reward, performed after other obligations have 
been fulfilled, and at times against the will of peers 
and superiors. 
Private industry has paid also in the form of 
subsidies of drugs, such as cyclosporine, and other 
biologic materials, such as antilymphocyte and anti-
thymocyte globulins, used in preliminary trials by 
patients and physicians involved in hepatic trans-
plantation. Besides providing such potentially useful 
experimental agents, many companies have either 
paid for or have developed assay systems for moni-
toring drug levels, biologic agent effectiveness, and 
the accumulation of data concerning both beneficial 
and adverse effects of the agents in which they have 
a vested interest. 
In addition to each of these individuals or 
groups, others, such as individual philanthropists, 
group philanthropies, various foundations and 
regional and national foundations having an interest 
in transplantation, liver disease, and health in 
general, have provided both funds and support for 
liver transplantation research and development and 
its clinical application. 
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Who Benefits from Liver Transplantation? 
This question, like the preceding one, is quite 
complex and the answer varies depending on the 
sophistication of the questioner, the responder, or 
both.19 A strong case can be made for liver trans-
plantation benefiting each of the following individ-
uals or groups: the patient, his or her family, pa-
tients of the future and their families, individuals 
with liver disease (including those not expected to 
require a transplant), clinical and basic researchers 
interested in such issues as the liver in general, 
transplantation, rejection, and hepatic regeneration 
in particular, and the broad area of hepatic patho-
physiology. Certainly physicians and surgeons 
caring for patients with liver disease now and in the 
future have and will continue to benefit from the 
experience accrued as a result of the clinical applica-
tion of liver transplantation. Society also benefits 
by the return of a formerly critically ill, incapaci-
tated consumer of health care and related benefits 
to a life that includes a return to gainful employ-
ment and the payment of health care premiums 
rather than the continued consumption of health 
care benefits. Society also benefits from the applica-
tion of lessons learned from hepatic transplanta-
tion, so that generations of people with liver disease 
in the future need not endure what patients with 
liver disease in the past have done. 
The benefits of a liver transplantation program 
extend to, and are appreciated by, all of the pa-
tients cared for by physicians and institutions in-
volved in the care of patients with liver disease, not 
just those institutions in which there is a clinical 
hepatic transplantation program. Liver transplanta-
tion centers benefit by becoming recognized as 
referral centers for patients with liver diseases, in-
cluding many with unusual or rare hepatic diseases. 
As a consequence, opportunities for the training of 
health professionals interested in liver disease be-
come available in such centers. Moreover, by con-
centrating patients with rare or unusual diseases at a 
few such specialized centers, useful clinical and 
research observations can be made and confirmed 
by physicians and scientists working at such special-
ized centers. Finally, by acting as a focus for 
physicians and scientists interested in issues such as 
transplantation, liver disease, and the many fields 
that intercept with these two broad areas, the in-
sights and efforts of the few investigators at such 
centers can be examined, reexamined, amplified, 
and then made available to society at large for use 
by individuals outside the center. Clearly, the bene-
fits are legion. 
COMMENT 
It is hoped the preceding discussion has helped 
to put in focus for physicians, surgeons, medical 
investigators, governmental as well as public and 
private funding agencies, and most importantly, the 
lay public, the many advantages associated with 
liver transplantation. The investment by each desig-
nated group has been and continues to be great. 
Nonetheless, the dividends to be gained by each and 
for society are clearly worth the investment and 
more. 
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